A Study Evaluating The Safety And Efficacy Of Daclatasvir (DCV) Plus Sofosbuvir (SOF) Regimens With Or Without Ribavirin (RBV) In Chronic Hepatitis C Virus Infected (HCV) Patients With Advanced Liver Fibrosis And Compensated Or Decompensated Cirrhosis.

Trial Profile

A Study Evaluating The Safety And Efficacy Of Daclatasvir (DCV) Plus Sofosbuvir (SOF) Regimens With Or Without Ribavirin (RBV) In Chronic Hepatitis C Virus Infected (HCV) Patients With Advanced Liver Fibrosis And Compensated Or Decompensated Cirrhosis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Jan 2017

At a glance

  • Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 30 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top